Loading organizations...
HealthQuest Capital: Growth equity firm investing in commercial-stage healthcare companies across medical devices, biopharma, and healthcare IT.
HealthQuest Capital is a leading growth equity and private equity firm based in Redwood City, California, dedicated to investing in commercial-stage healthcare companies poised for significant scaling. Founded in 2012 by Garheng Kong, the firm's managing partner, it strategically targets transformative innovations across medical devices, diagnostics, biopharma, healthcare IT, services, and pharma services. The primary objective is to improve patient outcomes and enhance overall healthcare value through its impactful investments. HealthQuest Capital manages approximately $2 billion in assets under management, boasting a robust portfolio of 52 companies and facilitating 23 total exits through successful IPOs and M&A transactions. Recognizable portfolio exits include Cempra, Alimera, and Applied Genetic Technology Corp., underscoring the firm's track record in fostering successful ventures. Garheng Kong has also been recognized as a significant figure in healthcare investing.
Key people at HealthQuest Capital.
Key people at HealthQuest Capital.
# HealthQuest Capital: Transforming Healthcare Through Growth Equity Investment
HealthQuest Capital is a growth equity and private equity firm dedicated to investing in commercial-stage healthcare companies poised for significant scaling[1][2]. Founded in 2012 and based in California, the firm manages approximately $2 billion in assets under management across 51 portfolio companies, with a track record of 23 exits[2].
The firm's mission centers on amplifying impact by investing in transformative healthcare companies that improve patient outcomes and enhance healthcare delivery efficiency[2]. Rather than pursuing early-stage venture investments, HealthQuest focuses exclusively on companies that have achieved commercial traction and are ready to scale their operations. The investment philosophy emphasizes partnership and active involvement—the firm positions itself not as a passive capital provider but as an agent of positive change, leveraging its team's 300+ years of combined operating and investing experience to support portfolio companies through their growth phases[2].
HealthQuest's reach is substantial: its portfolio companies collectively serve approximately 95 million patients across 60 countries, partner with over 3,000 hospitals, and reach approximately 300 million insured lives through roughly 6,500 employer partnerships[1]. This scale demonstrates the firm's ability to identify and support companies with meaningful market impact.
HealthQuest Capital was established in 2012, positioning itself at a critical inflection point in healthcare innovation when commercial-stage healthcare companies were increasingly seeking growth capital beyond traditional venture funding[5]. The firm emerged from a recognition that transformative healthcare innovations required not just capital, but strategic operational support and deep industry expertise to scale effectively.
The founding reflected a deliberate strategy to focus on a specific market gap: commercial-stage healthcare companies that had proven product-market fit but needed experienced partners to navigate expansion, market penetration, and operational scaling. By assembling a team with extensive operating and investing backgrounds, HealthQuest built credibility with both portfolio companies and limited partners seeking healthcare-focused growth investments.
HealthQuest's primary differentiation lies in its exclusive focus on commercial-stage companies ready to scale[2]. This contrasts sharply with venture capital firms that pursue earlier-stage opportunities. The firm employs two complementary strategies—Growth Equity and Tactical Opportunities—allowing it to deploy flexible capital structures tailored to each company's unique needs[2]. This flexibility enables the firm to serve as a true partner rather than a one-size-fits-all capital provider.
The firm invests across the entire healthcare landscape, including medical devices and technologies, healthcare services, diagnostics, healthcare IT, and pharma services[1][2]. This diversification reduces concentration risk while allowing the firm to identify cross-portfolio synergies. Importantly, HealthQuest's focus transcends specific healthcare modalities, instead honing in on commercial prospects that drive enhanced patient outcomes and operational efficiency[1].
HealthQuest distinguishes itself through its Industry Advisory Board and strategic limited partner network, positioning itself as "the best-connected firm in healthcare investing"[2]. The team's 300+ years of combined experience translates into hands-on operational support—the firm functions as an active partner in scaling operations, expanding market presence, and enhancing value propositions[2]. This operating-partner model differentiates HealthQuest from purely financial investors.
With 23 exits from its portfolio, HealthQuest has demonstrated consistent ability to identify winners and create value[2]. Recent portfolio exits illustrate the caliber of companies the firm backs: HistoSonics announced a $2.25 billion acquisition by a consortium of top-tier investors in August 2025, and Terumo's acquisition of OrganOx Limited in August 2025 marked a strategic entry into organ transplantation technology[1].
HealthQuest operates at the intersection of several powerful healthcare trends. The firm is positioned to capitalize on the structural shift toward healthcare innovation, where commercial-stage companies increasingly require growth capital to compete with larger incumbents and expand into new markets. The timing is particularly favorable given accelerating healthcare digitalization, the rise of alternative delivery models, and growing demand for diagnostic and therapeutic innovations.
The firm's portfolio composition reflects these trends: investments span telehealth expansion (Remedy Meds acquiring Thirty Madison in September 2025), organ preservation technology, and healthcare IT solutions[1]. By backing companies addressing these secular trends, HealthQuest influences the broader ecosystem by determining which healthcare innovations achieve scale and market dominance.
Furthermore, HealthQuest's emphasis on patient outcomes and healthcare delivery efficiency aligns with broader industry movements toward value-based care and operational excellence. The firm's portfolio impact—reaching 95 million patients across 60 countries—demonstrates how growth equity capital, when deployed strategically, can accelerate healthcare transformation at scale.
HealthQuest Capital has established itself as a premier growth equity platform in healthcare by combining deep industry expertise, operational support, and strategic capital deployment. The firm's $2 billion AUM and 51-company portfolio position it to continue identifying and scaling transformative healthcare innovations.
Looking forward, several trends will likely shape HealthQuest's trajectory. First, the continued consolidation of healthcare services and the rise of healthcare platforms will create opportunities for growth equity capital to support scaling. Second, the acceleration of healthcare technology adoption—from AI-driven diagnostics to digital therapeutics—will generate deal flow aligned with HealthQuest's investment thesis. Third, the firm's demonstrated ability to support exits at scale (evidenced by recent multi-billion-dollar acquisitions) will enhance its reputation and LP fundraising capacity.
The firm's future influence will likely expand as healthcare innovation increasingly requires not just capital but operational partnership and strategic guidance. HealthQuest's model—combining patient-outcome focus with rigorous financial discipline—positions it to remain a central player in determining which healthcare innovations achieve transformative scale. As healthcare systems globally seek efficiency gains and improved outcomes, firms like HealthQuest that back commercial-stage innovators will play an outsized role in shaping the industry's evolution.
